Idorsia (OTCMKTS:IDRSF) Downgraded to “Hold” at Jefferies Financial Group

Jefferies Financial Group lowered shares of Idorsia (OTCMKTS:IDRSFGet Rating) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning, The Fly reports.

Several other equities research analysts have also issued reports on the stock. JPMorgan Chase & Co. lowered their target price on shares of Idorsia from CHF 17 to CHF 15 and set a neutral rating on the stock in a research note on Tuesday, January 3rd. Deutsche Bank Aktiengesellschaft lowered shares of Idorsia from a buy rating to a hold rating in a research note on Friday, October 21st. Finally, Credit Suisse Group lowered shares of Idorsia from an outperform rating to a neutral rating in a research note on Thursday, November 10th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Idorsia currently has a consensus rating of Hold and a consensus price target of $22.50.

Idorsia Price Performance

IDRSF stock opened at $18.84 on Wednesday. The company’s 50-day simple moving average is $15.08 and its 200-day simple moving average is $14.44. Idorsia has a 52-week low of $11.62 and a 52-week high of $24.30.

Idorsia Company Profile

(Get Rating)

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.

Featured Stories

The Fly logo

Analyst Recommendations for Idorsia (OTCMKTS:IDRSF)

Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.